Stock AnalizAbbVie (ABBV) earnings for the quarter ended September 2026: EPS beats estimates
AbbVie reported results for the quarter ended September 2026 on October 30, 2026. Adjusted earnings per share came in at $3.82 against the analysts’ average forecast of $3.76, a beat of 1.5%.
Revenue for the quarter was $17.40 billion, up 10.3% from $15.78 billion in the same quarter a year earlier.
The market’s verdict: the stock rose 1.4% on the first trading day after the report.
The last four quarters
AbbVie has beaten the analysts’ EPS forecast in 3 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | $3.82 | $3.76 | +1.5% | +10% | +1.4% |
| Jun 2026 | $3.65 | $3.61 | +1.1% | +10% | −4.8% |
| Mar 2026 | $2.65 | $2.67 | −0.8% | +12% | +6.9% |
| Dec 2025 | $2.71 | $2.65 | +2.2% | +10% | −2.9% |
What comes next
Analysts expect EPS of $3.88 for the next quarter on average and $13.98 for the fiscal year ending December 31, 2026.
The average analyst price target is $311.81, 6% above the current price of $295.03.
Valuation and score
AbbVie scores 1.8 out of 5 overall on Stock Analiz (weak), trades at a trailing P/E of about 50.8, and its intrinsic value under moderate assumptions is about 20% below the current market value. Full AbbVie analysis with 10 years of financials
Frequently asked questions
What was AbbVie’s EPS for the quarter ended September 2026?
$3.82 adjusted per share, against an analyst consensus of $3.76.
How much revenue did AbbVie report?
$17.40 billion, up 10.3% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.